Abstract
Somatostatin receptor subtype 2 upregulation is very common in meningiomas, and the use of peptide receptor radionuclide therapy (PRRT) is recognized in recent European guidelines, with long-term stable disease and a long overall survival. Treatment efficacy of radionuclide treatments is correlated with tumour radiation absorbed dose. Meningioma patients with low tumour uptake might benefit less from treatment. Thus, a method to increase tumour uptake in these patients is needed. We describe a case treated with both intravenous and intra-arterial PRRT. Tumour uptake after intravenous PRRT was disappointing, and after intra-arterial administration significantly increased tumour uptake was seen. Patient had a partial response on imaging and reduction in tumour-related complaints. Potentially, intra-arterial administration of PRRT could increase treatment efficacy in meningioma patients.Level of Evidence 5 (case report).
| Original language | English |
|---|---|
| Pages (from-to) | 1649-1652 |
| Number of pages | 4 |
| Journal | Cardiovascular and Interventional Radiology |
| Volume | 42 |
| Issue number | 11 |
| Early online date | 11 Jun 2019 |
| DOIs | |
| Publication status | Published - Nov 2019 |
Keywords
- Lu-177-HA-DOTATATE
- Meningioma
- Neuro-oncology
- PRRT
Fingerprint
Dive into the research topics of 'Will Lu-177-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration: A Promising Case on Intra-arterial Administration'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver